Get the Stockscreener App
7.38
0.54%
0.04
After Hours:
7.43
0.05
+0.68%
Kezar Life Sciences Inc stock is traded at $7.38, with a volume of 132.72K.
It is up +0.54% in the last 24 hours and down -0.27% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$7.34
Open:
$7.35
24h Volume:
132.72K
Relative Volume:
1.77
Market Cap:
$54.52M
Revenue:
$7.00M
Net Income/Loss:
$-56.03M
P/E Ratio:
-0.9636
EPS:
-7.6589
Net Cash Flow:
$-51.79M
1W Performance:
+1.10%
1M Performance:
-0.27%
6M Performance:
+21.98%
1Y Performance:
+77.40%
1-Day Range:
$7.345
$7.42
1-Week Range:
$7.23
$7.42
52-Week Range:
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.38 | 54.23M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-17-25 | Downgrade | Jefferies | Buy → Hold |
| Oct-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Kezar Life Sciences (KZR) Expected to Announce Earnings on Tuesday - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Pharma Co. Investor Sues Over Misleading Aurinia Deal - Law360
Kezar Life Sciences, Inc. 2025 Executive Compensation, Equity Ownership, and Corporate Governance Overview 171819224546 - Minichart
Kezar Life Sciences (NASDAQ: KZR) details Aurinia tender offer, pay and ownership - Stock Titan
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Large Decrease in Short Interest - MarketBeat
Kezar Life Sciences (KZR) Registration Filing Summary - Quartr
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
KZR Kezar Life Sciences Inc. reports far wider Q4 2025 loss than estimates even as shares edge higher.Revenue Diversification - Cổng thông tin điện tử Tỉnh Sơn La
Kezar Life (KZR) Stock: Reasonably Valued? (Volatility Increases) 2026-04-20Hot Market Picks - Cổng thông tin điện tử tỉnh Tây Ninh
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? - Benzinga
M&A Class Action Firm Investigating Multiple Mergers - National Today
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Working capital per share of Kezar Life Sciences Inc – FWB:2KZ0 - TradingView
KZR Technical Analysis & ETF Price Forecast - Intellectia AI
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - GuruFocus
Weekly Trades: Will Kezar Life Sciences Inc announce a stock splitInsider Buying & Safe Swing Trade Setups - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Published on: 2026-04-10 03:01:28 - baoquankhu1.vn
Sectors Review: What are Kezar Life Sciences Incs recent SEC filings showing2026 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS - Sahm
Is Kezar Life (KZR) Stock Breaking Out | KZR Q4 Earnings: Misses Estimates by $0.74Collaborative Trading Signals - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, CNTA, AFBI, and APLS - Morningstar
Growth Value: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
What limits growth of Kezar Life (KZR) Stock | Price at $7.38, Down 0.14%Community Risk Signals - Newser
Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? - Finviz
Pullback Watch: What is the next catalyst for Kezar Life Sciences Inc2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Shareholder Alert: Ademi LLP investigates whether Kezar - GlobeNewswire
Baselake reports 5.3% stake in Kezar Life Sciences (NASDAQ: KZR) - Stock Titan
Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
KZR Q4 2025 Earnings: Kezar Life Sciences Inc. Misses EPS, No RevenueCrowd Sentiment Stocks - Newser
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - Investing.com South Africa
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):